Polaris Partners

Activity from announced rounds

All recorded activity
Rounds participated in
6
Confirmed lead rounds
0
4 roles undisclosed
New companies
6
First participation on record · 0 follow-on
Funding in participating rounds
$423.3M
6 disclosed · full round size, not this investor’s share

By stage

Series B4
Series A1
Undisclosed1

By primary sector

Biotech5
Healthtech1

By country

United States6

Rounds

6 in all activity
Soufflé Therapeutics

Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.

$135MSeries B
Participant
Faro AI

Structured data and AI agents for clinical development and pharmaceutical trial operations.

$37.3MSeries B
Participant
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed
EpiBiologics

Develops bispecific antibodies for targeted degradation of extracellular proteins.

$107MSeries B
Role not disclosed